Ultragenyx Pharmaceutical opened lower at $16.48, compared with its previous close of $16.70. In the last trading session, the stock traded between $16.16 and $16.62. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Ultragenyx Pharmaceutical is now worth
$ 19.87
Resulting in a loss of
$ 80.13 (80.13%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 20 Analysts
Buy
45%
Hold
55%
Sell
0%
Markets Today
Today's Change
$-0.43 (-2.59%)
Day High
$16.62
Day Low
$16.16
Day Open
$16.48
Prev Close
$16.70
Volume
30,59,571
1W Return
-5.14%
1M Return
6.38%
3M Return
-39.62%
6M Return
-38.14%
1Y Return
-51.07%
Fundamentals
Market Cap ($ Mn)
1,658
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-599.34%
ROCE
-51.44%
EPS (TTM)
$-1.16
Investment Returns
1 Week
-5.14%
1 Month
6.38%
3 Months
-39.62%
6 Months
-38.14%
9 Months
-31.88%
Financials
Quarterly
All values in $ Mn
139.3
Mar 25
166.5
Jun 25
159.9
Sep 25
207.3
Dec 25
214.0
Jun 26
173.0
Sep 26
Updates
6Nov
Ultragenyx aligns NICE evaluation with MHRA review of UX111
MHRA accepted Ultragenyx's MAA for rebisufligene etisparvovec on October 28, 2026. Company aligns NICE evaluation with MHRA review to secure NHS access for Sanfilippo Type A. Therapy received FDA approval in September 2026; EMA review initiated in October 2026.
6 days ago
6Nov
Citigroup maintains Buy on Ultragenyx, cuts price target to $22
Citigroup maintained a Buy rating on Ultragenyx Pharmaceutical. Price target lowered from $32 to $22 by analyst Yigal Nochomovitz. Rating status remains unchanged despite the valuation cut.
7 days ago
6Nov
Barclays lowers Ultragenyx price target to $32, keeps overweight
Barclays lowered Ultragenyx Pharmaceutical's price target from $35 to $32. The firm maintained an Overweight rating on the stock. Analyst Eliana Merle issued the revised price target.
7 days ago
5Nov
Canaccord Genuity maintains Buy on Ultragenyx, cuts target to $34
Canaccord Genuity maintains a Buy rating on Ultragenyx Pharmaceutical. Price target lowered from $39 to $34. Analyst Whitney Ijem issued the revised rating.
TD Cowen maintains a Buy rating on Ultragenyx Pharmaceutical. Price target raised from $18 to $19. Analyst Yaron Werber led the rating action.
8 days ago
5Nov
Morgan Stanley lifts Ultragenyx price target to $22, keeps equal-weight
Morgan Stanley raised Ultragenyx Pharmaceutical's price target from $20 to $22. The firm maintained an Equal-Weight rating on the stock. Analyst Maxwell Skor made the revision in his latest report.
